Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic
Lubrizol and Welton Aim to Address The Challenge of Cancer Drug Solubility
Welton will combine their expertise with Lubrizol's Apisolex excipient designed for parenteral applications to develop a novel formulation of SN-38 to treat colorectal and associated gastro-intestinal cancers
